VYNDAMAX® (tafamidis) PBS-listed for adult patients with wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM) with New York Heart Association (NYHA) Class I-II heart failure
SYDNEY, May 4, 2024 /PRNewswire/ -- Pfizer Australia has welcomed the announcement that VYNDAMAX® (tafamidis), which is approved in Australia for adult